Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.
This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.
This page shows the 17 of those studies listing the condition Relapsed or Refractory Multiple Myeloma.
11 of the 17 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 2 have not yet opened recruitment, 4 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.
| Phase | Studies | Recruiting | Share |
|---|---|---|---|
| Phase 1 | 7 | 4 | 41.2% |
| Phase 3 | 5 | 3 | 29.4% |
| Phase 1/2 | 2 | 2 | 11.8% |
| Phase 2 | 2 | 2 | 11.8% |
| Phase EARLY_PHASE1 | 1 | 0 | 5.9% |
| Lead sponsor | Studies | Recruiting |
|---|---|---|
| Qilu Pharmaceutical Co., Ltd. | 3 | 2 |
| Janssen Research & Development, LLC | 2 | 0 |
| Beijing Mabworks Biotech Co., Ltd. | 1 | 1 |
| Bristol-Myers Squibb | 1 | 0 |
| Celgene | 1 | 1 |
| Excyte Biopharma Ltd | 1 | 1 |
| Guangdong Second Provincial General Hospital | 1 | 0 |
| Hangzhou Sumgen Biotech Co., Ltd. | 1 | 0 |
| Innovent Biologics (Suzhou) Co. Ltd. | 1 | 1 |
| Institute of Hematology & Blood Diseases Hospital, China | 1 | 1 |